Pharmacokinetic Study of Single and Multiple Dose of PKL-021 Administered Orally to Healthy Subjects
This study is investigating a new medicine called PKL-021. The main goal is to understand how your body handles this medicine. This includes how it's absorbed after you swallow it, how long it stays in your system, and how your body gets rid of it. Researchers will be looking at what happens when healthy volunteers take just one dose, and also when they take it regularly over a period of time. This kind of study, often called an early-stage or Phase 1 study, is really important for new medicines. It helps scientists work out the safest and most effective way to give the medicine to people in future, making sure it gets to where it needs to go in the body and doesn't cause too many side effects. It's a key first step before testing the medicine in people who are unwell.
At a glance
What is this study about?
This research study is about a new medicine called PKL-021. It's a very early-stage study, which means it's one of the first times this medicine is being given to people. The main aim is to understand how the medicine behaves inside the human body. Think of it like this: when you take a pill, your body starts to process it. This study wants to find out how quickly the medicine gets into your blood, how long it stays there, and how your body eventually removes it. This process is often called 'pharmacokinetics.'
Researchers will be giving the medicine to healthy volunteers in two different ways. Some volunteers will receive just one dose of PKL-021, and others will receive it regularly over a short period. By comparing what happens with a single dose versus multiple doses, the researchers can learn a lot. This helps them understand if the body handles the medicine differently over time and if it builds up in your system.
Why is this important? All new medicines need to go through these early studies. The information gathered here is crucial for future steps. It helps scientists decide what dose of the medicine to use, how often it should be given, and if it's safe enough to move on to studies with people who have a particular illness. This foundational knowledge makes sure that when the medicine is eventually given to patients, it has the best chance of working effectively and safely.
Key takeaways
- This is an early study of a new medicine called PKL-021.
- It aims to understand how the medicine works in healthy people.
- Participants take one dose or multiple doses of the medicine.
- Learning how the body handles the medicine helps future drug development.
- It's open to healthy men and women aged 18 and over.
- Your participation helps advance medical understanding for future patients.
Who may be eligible?
This study is specifically looking for healthy volunteers. This means you should generally be in good health and not have any serious ongoing medical conditions.
You must be at least 18 years old to take part. There is no upper age limit, so adults of any age are welcome to consider participating.
Both men and women are invited to join this study. The researchers want to understand how the medicine works in everyone.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you generally healthy?
- Are you 18 years old or older?
- Do you not have any serious ongoing medical conditions?
- Are you able to commit to the study visits and procedures?
What does participation involve?
As this is a very early-stage study, participation typically involves several visits to a clinic or research centre. You would likely undergo a screening visit to check your overall health and eligibility. If you qualify, you might be admitted to a research unit for a period, which could range from a few days to a couple of weeks, especially for the multiple-dose part of the study. During this time, you would receive the PKL-021 medicine.
Assessments usually include regular blood and urine tests to track how the medicine moves through your body, as well as blood pressure, heart rate, and temperature checks to monitor your general health. You may also be asked to complete questionnaires about how you are feeling. After the main dosing period, there might be follow-up visits or phone calls to ensure everything is okay. The total duration of your involvement, from screening to the final follow-up, would be clearly explained by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedCzechia
Common questions
What does 'pharmacokinetic' mean?
It's a fancy word researchers use to describe how your body handles a medicine – how it's taken in, moves around, and leaves your system.
Will I get better if I take part?
Because you're healthy to begin with, this study isn't designed to make you feel better. It helps researchers learn about a new medicine for others.
Do I need to be ill to join?
No, quite the opposite! This study is specifically looking for healthy people to help understand how the medicine works normally.
Will I have to stay in a clinic?
For early-stage studies like this, it's quite common for participants to stay at a research clinic for a few days or longer, especially for the multiple-dose part.
What if I change my mind after joining?
You are always free to withdraw from the study at any point, without needing to give a reason, and it won't affect your future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.